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The normal HCT trial re-revisited:
what were the actual findings?
To the Editor: Below is our response to the open com-
mentary1 on the Normal Hematocrit Cardiac Trial (NHCT).
K The academic coauthors of the New Engl J Med
(NEJM) report2 of the NHCT urge readers to revisit
the publication, which definitively does not recom-
mend use of epoetin to target hematocrit 42%.
Dr Coyne’s commentary in KI does not cite this
conclusion, implying that benefit occurred at higher
hematocrit.
K The commentary describes statistical reporting
‘discrepancies’, but fails to acknowledge that we
originally submitted the nominal P-value of 0.01 for
the primary end point, replaced in the manuscript
by repeated confidence intervals methodology
following NEJM editorial comment and external
statistician input.3
K The manuscript submitted to the NEJM stated, ‘There
were no statistically significant differences in quality-
of-life scores between groups or over time, using
intent-to-treat analysisy and assigning scores of zero
for patients who had died’. This sentence was deleted
by the editors, with only ‘improved physical function
scores among 12-month survivors with increases in
hematocrit’ remaining. Epoetin responders may have
different outcomes than nonresponders.
K The NEJM paper reported a statistically insignificant
higher rate of hospitalization among the target 42%
group, no different from the KI commentary in that
the adjusted risk of hospitalization was insigni-
ficantly different (P¼ 0.06).
K Aggregate non-access thrombotic events (22% vs.
18%) were added to the epoetin alfa package insert,
but were reported only by individual events in the
NEJM.
K All coauthors of the NEJM paper had full access to
the patient data and contributed to each revision.
This was the first large study to report adverse
outcomes associated with targeting normal hema-
tocrit in chronic kidney disease. There was no intent
to mislead anyone.
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The Author Replies: Despite no attempt to mislead,1 each
discrepancy favored consideration of targeting hematocrit
433%.2 One author’s subsequent commentary encouraged
hematocrit normalization, stating the trial showed ‘signiﬁcant
improvements in QOL parameters in the patients in the
normal (hematocrit) groupy’.3 We now understand the
publication merely observed that those in the high arm with
higher ‘physical function’ scores achieved higher hemato-
crit.2,4 Unstated was the fact that the low arm had just as
many patients with higher ‘physical function’ scores. Target-
ing hematocrit 433% raised no one’s quality of life. Mean
scores declined identically in both groups, and did not differ
at 12 months (P¼ 0.97).4 Guideline groups and physicians are
now better informed.
A P¼ 0.01 for all-cause death was acknowledged 11 years
after the original publication following Food and Drug
Administration (FDA) disclosure,1,2 but did not report the hazard
ratio of 1.27 and 95% conﬁdence interval of 1.04–1.54.4
I stated that the editors in 1998 agreed to publication of only
adjusted primary outcome results, and by implication the
omission of the death statistics.4
Increased hospitalizations strongly suggest higher medical
costs. Targeting normal hematocrit signiﬁcantly increased
hospitalizations in the primary predeﬁned analysis (P¼ 0.04),
and showed a trend in an adjusted predeﬁned analysis
(P¼ 0.06),4 whereas the authors in 1998 and now promote
the neutral post hoc analysis (P¼ 0.30).2 A revised FDA label,
but not the 1998 publication, reported predeﬁned thrombotic
rates (22% vs. 18%), but provided no statistical result. It was
P¼ 0.041.4
If the 1998 publication discouraged targeting hematocrit to
42%, the results indicate targeting 433% provides no beneﬁt
beyond reduced transfusions. That important difference
contributed to billions in expenditure.
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